The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.
Michael J. Morris
No relevant relationships to disclose
Neeta Pandit-Taskar
No relevant relationships to disclose
Scott T. Tagawa
No relevant relationships to disclose
David M. Nanus
No relevant relationships to disclose
Stephen Barnett Solomon
No relevant relationships to disclose
Jorge A. Carrasquillo
No relevant relationships to disclose
Victor E. Reuter
No relevant relationships to disclose
Jason Stuart Lewis
No relevant relationships to disclose
Volkan Beylergil
No relevant relationships to disclose
Joseph A. O' Donoghue
No relevant relationships to disclose
Serge K. Lyashchenko
No relevant relationships to disclose
Danny F. Martinez
No relevant relationships to disclose
Kristen Rebecca Curtis
No relevant relationships to disclose
Jeremy C. Durack
No relevant relationships to disclose
Sarah M. Cheal
No relevant relationships to disclose
Neil Harrison Bander
Consultant or Advisory Role - BZL Biologics
Stock Ownership - BZL Biologics
Howard I. Scher
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose